{
  "title": "Performance Status",
  "category": "Clinical Oncology",
  "section": "Patient Assessment",
  "summary": "A comprehensive guide to performance status assessment in oncology practice, including tools, clinical implications, and future directions.",
  "author": "OncoVISTA Team",
  "lastUpdated": "2023-10-20T00:00:00Z",
  "version": "1.0.0",
  "metadata": {
    "reviewStatus": "peer-reviewed",
    "readingTimeMinutes": 10
  },
  "content": [
    {
      "type": "heading",
      "level": 1,
      "text": "Performance Status"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Topic 9: Key Takeaways"
    },
    {
      "type": "paragraph",
      "text": "Expanded and clinically contextualized for practice, research, and education"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "1. Definition and Purpose"
    },
    {
      "type": "paragraph",
      "text": "Performance status (PS) is a clinician-assessed summary measure of a patient's ability to perform everyday activities. It is one of the most consistently used clinical predictors in oncology. PS reflects underlying physiologic reserve, and thus directly impacts decisions regarding:"
    },
    {
      "type": "list",
      "items": [
        "Treatment intensity",
        "Clinical trial eligibility",
        "Prognosis and survival",
        "Referral to palliative or supportive care"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "PS should be interpreted dynamically, with reassessment at every clinical milestone."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "2. Core Performance Status Tools Overview"
    },
    {
      "type": "table",
      "headers": ["Tool", "Target Population", "Score Range", "Clinical Notes"],
      "rows": [
        ["ECOG", "Adults (standard use)", "0–5", "Simple, rapid; standard for trials and systemic therapy decisions"],
        ["KPS", "Adults (esp. palliative, neuro-oncology)", "0–100", "Higher resolution; more sensitive to functional trajectory"],
        ["Lansky", "Pediatrics (1–16 years)", "0–100", "Behavior- and play-based; caregiver input essential"]
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Use ECOG or KPS depending on context; for pediatrics, always apply Lansky."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "3. Beyond Standard PS: Geriatric and Frailty Tools"
    },
    {
      "type": "paragraph",
      "text": "ECOG/KPS alone often miss hidden vulnerabilities in older patients. Supplement with:"
    },
    {
      "type": "list",
      "items": [
        "CGA (Comprehensive Geriatric Assessment): Full multidomain evaluation",
        "G8: 8-item screening for early frailty detection",
        "CFS: Rapid bedside frailty stratification (1–9 scale)",
        "VES-13: 13-item functional vulnerability tool",
        "Balducci Classification: Clinically segments elderly into fit, vulnerable, and frail"
      ]
    },
    {
      "type": "paragraph",
      "text": "These tools are predictive of toxicity, hospitalization, and mortality, especially when ECOG is 1–2."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "4. Treatment Planning Based on PS"
    },
    {
      "type": "table",
      "headers": ["PS Category", "Interpretation", "Clinical Action"],
      "rows": [
        ["Good (ECOG 0–1, KPS ≥80)", "Fully functional, active", "Full-dose chemotherapy, surgery, trials"],
        ["Intermediate (ECOG 2)", "Ambulatory but functionally limited", "Dose-reduced or monotherapy; assess for CGA"],
        ["Poor (ECOG ≥3, KPS <50)", "Dependent, symptomatic", "Palliative care focus; avoid high-toxicity regimens"]
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Poor PS is a key signal to re-evaluate treatment goals and prioritize quality of life."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "5. Clinical Trial Implications"
    },
    {
      "type": "paragraph",
      "text": "PS has historically been used to standardize safety in trials, but this may exclude patients most representative of real-world practice."
    },
    {
      "type": "list",
      "items": [
        "Most Phase II/III trials require ECOG ≤1",
        "Elderly and ECOG ≥2 patients are underrepresented",
        "Innovative trials now use:"
      ]
    },
    {
      "type": "numbers",
      "items": [
        "PS stratification arms",
        "CGA-guided eligibility",
        "Inclusion of real-world data (RWD) cohorts"
      ]
    },
    {
      "type": "paragraph",
      "text": "Regulatory trend: Increasing pressure to balance safety with inclusivity and relevance."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "6. Pediatric and Elderly Considerations"
    },
    {
      "type": "paragraph",
      "text": "In children, PS must be contextualized by:"
    },
    {
      "type": "list",
      "items": [
        "Developmental stage",
        "Play and school function",
        "Use Lansky Scale (0–100)"
      ]
    },
    {
      "type": "paragraph",
      "text": "In older adults:"
    },
    {
      "type": "list",
      "items": [
        "Combine ECOG with frailty measures",
        "Assess ADLs, cognition, nutrition, caregiver support"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "PS interpretation must go beyond the score and into the life context of the patient."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "7. When to Reassess PS"
    },
    {
      "type": "paragraph",
      "text": "Performance status is not static. It should be re-evaluated:"
    },
    {
      "type": "list",
      "items": [
        "At diagnosis",
        "Before starting a new treatment line",
        "After hospitalization or treatment toxicity",
        "At any point of clinical decline or new symptoms",
        "During goals-of-care or hospice discussions"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Always document changes and their clinical impact."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "8. Future Directions"
    },
    {
      "type": "paragraph",
      "text": "Emerging technologies are modernizing PS:"
    },
    {
      "type": "list",
      "items": [
        "Wearables: Step count, mobility, activity duration",
        "Mobile health apps: Daily fatigue, mood, pain input",
        "AI models: Infer PS from EMR notes, labs, imaging",
        "Remote CGA: Digital geriatric assessments via telemedicine"
      ]
    },
    {
      "type": "paragraph",
      "text": "These tools promise to make PS more objective, continuous, and patient-centered."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "9. Ethical Use of PS"
    },
    {
      "type": "paragraph",
      "text": "PS must never be used punitively. Instead, it should:"
    },
    {
      "type": "list",
      "items": [
        "Guide realistic conversations about treatment options",
        "Help patients and caregivers understand risks vs benefit",
        "Ensure decisions are goal-aligned and ethically sound",
        "Avoid systemic biases in interpreting PS, especially in underserved populations"
      ]
    },
    {
      "type": "clinical_pearl",
      "text": "Quote for framing: \"Your strength and daily function give us a sense of what treatments will help — and which might cause harm. Let's decide what fits best with your goals.\""
    },
    {
      "type": "heading",
      "level": 2,
      "text": "10. Final Summary"
    },
    {
      "type": "paragraph",
      "text": "Performance status remains a foundational pillar of oncology care. Used wisely, it can:"
    },
    {
      "type": "list",
      "items": [
        "Clarify who benefits from therapy",
        "Support personalized, age-appropriate care",
        "Inform palliative or hospice transitions",
        "Strengthen multidisciplinary planning and communication"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Key principles to remember:"
    },
    {
      "type": "list",
      "items": [
        "Select the right tool for age, setting, and decision",
        "Supplement ECOG/KPS with geriatric and psychosocial insights",
        "Reassess frequently and document clearly",
        "Embrace technology to enhance, not replace, clinical judgment"
      ]
    }
  ]
}